CRSP
CRSP
NASDAQ · Biotechnology

Crispr Therapeutics Ag

$46.43
-0.45 (-0.96%)
As of Mar 24, 9:54 PM ET ·
Financial Highlights (FY 2026)
Revenue
3.73M
Net Income
-618,566,079
Gross Margin
Profit Margin
-16,569.8%
Rev Growth
+43.0%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 54.8% 54.8%
Operating Margin -18,933.6% -17,040.3% -11.6% -11.4%
Profit Margin -16,569.8% -15,741.3% -12.2% -11.8%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 3.73M 2.61M 1.10B 1.10B
Gross Profit 601.13M 602.78M
Operating Income -706,223,062 -444,444,972 -127,445,861 -125,238,954
Net Income -618,566,079 -389,280,100 -133,819,624 -129,413,867
Gross Margin 54.8% 54.8%
Operating Margin -18,933.6% -17,040.3% -11.6% -11.4%
Profit Margin -16,569.8% -15,741.3% -12.2% -11.8%
Rev Growth +43.0% +43.0% +24.0% +12.2%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 1.78B 1.51B
Total Equity 2.90B 2.79B
D/E Ratio 0.61 0.54
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -593,986,408 -394,578,762 -179,167,841 -179,074,292
Free Cash Flow -115,939,335 -83,372,083